Other
Silibinin
Silibinin is an intervention with 6 clinical trials. Currently 2 active trials ongoing. Historical success rate of 50.0%.
Total Trials
6
Max Phase
—
Type
OTHER
Molecule
—
Success Metrics
Clinical Success Rate
50.0%
Based on 2 completed trials
Completion Rate
50%(2/4)
Active Trials
2(33%)
Results Posted
50%(1 trials)
Terminated
2(33%)
Phase Distribution
Ph phase_1
1
17%
Ph phase_2
3
50%
Ph not_applicable
2
33%
Phase Distribution
1
Early Stage
3
Mid Stage
0
Late Stage
Phase Distribution6 total trials
Phase 1Safety & dosage
1(16.7%)
Phase 2Efficacy & side effects
3(50.0%)
N/ANon-phased studies
2(33.3%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
50.0%
2 of 4 finished
Non-Completion Rate
50.0%
2 ended early
Currently Active
2
trials recruiting
Total Trials
6
all time
Status Distribution
Active(2)
Completed(2)
Terminated(2)
Detailed Status
Completed2
Terminated2
Recruiting1
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
6
Active
2
Success Rate
50.0%
Most Advanced
Phase 2
Trials by Phase
Phase 11 (16.7%)
Phase 23 (50.0%)
N/A2 (33.3%)
Trials by Status
recruiting117%
completed233%
terminated233%
active_not_recruiting117%
Recent Activity
2 active trials
Showing 5 of 6
active_not_recruitingnot_applicable
Prospective Double Arm Randomized Trial: WBRT Alone and WBRT Plus Silibinin
NCT05793489
recruitingnot_applicable
SILibinin in NSCLC and BC Patients With Single Brain METastasis (SILMET)
NCT05689619
terminatedphase_2
Intravenous Milk Thistle (Silibinin-Legalon) for Hepatic Failure Induced by Amatoxin/Amanita Mushroom Poisoning
NCT00915681
completedphase_1
Trial of Indole-3-Carbinol and Silibinin
NCT03687073
completedphase_2
Intravenous Silibinin in Combination With Peg-interferon and Ribavirin in Nonresponders
NCT00684268
Clinical Trials (6)
Showing 6 of 6 trials
NCT05793489Not Applicable
Prospective Double Arm Randomized Trial: WBRT Alone and WBRT Plus Silibinin
NCT05689619Not Applicable
SILibinin in NSCLC and BC Patients With Single Brain METastasis (SILMET)
NCT00915681Phase 2
Intravenous Milk Thistle (Silibinin-Legalon) for Hepatic Failure Induced by Amatoxin/Amanita Mushroom Poisoning
NCT03687073Phase 1
Trial of Indole-3-Carbinol and Silibinin
NCT00684268Phase 2
Intravenous Silibinin in Combination With Peg-interferon and Ribavirin in Nonresponders
NCT01535092Phase 2
Legalon SIL for the Treatment of HCV Recurrence in Liver Transplanted Patients
All 6 trials loaded
Drug Details
- Intervention Type
- OTHER
- Total Trials
- 6